Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Comparative Analysis Of Adverse Events Between Infl Iximab And Adalimumab In Crohn's Disease Management: A Brazilian Single-centre Experience [análise Comparativa Dos Eventos Adversos Entre Infliximabe E Adalimumabe No Tratamento Da Doença De Crohn: Experiěncia Em Um Centro Brasileiro]|
|Abstract:||Introduction: Data is scarce regarding adverse events (AE) of biological therapy used in the management of Crohn's Disease (CD) among Brazilian patients. Objectives: To analyse AE prevalence and profile in patients with CD treated with Infliximab (IFX) or Adalimumab (ADA) and to verify whether there are differences between the two drugs. Method: Retrospective observational single-centre study of CD patients on biological therapy. Variables analysed: Demographic data, Montreal classifi cation, biological agent administered, treatment duration, presence and type of AE and the need for treatment interruption. Results: Forty-nine patients were analysed, 25 treated with ADA and 24 with IFX. The groups were homogeneous in relation to the variables studied. The average follow-up period for the group treated with ADA was 19.3 months and 21.8 months for the IFX group (p = 0.585). Overall, 40% (n = 10) of patients taking ADA had AE compared with 50% (n = 12) of IFX users (p = 0.571). There was a tendency towards higher incidence of cutaneous and infusion reactions in the IFX group and higher incidence of infections in the ADA treated group, although without significant difference. Conclusions: No difference was found in the AE prevalence and profile between ADA and IFX CD patients in the population studied. © 2013 Elsevier Editora Ltda. All rights reserved.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.